Acitretin
From Wikipedia, the free encyclopedia
 |
|
|
Acitretin
|
|
| Systematic (IUPAC) name | |
| 9-(4-methoxy-2,3, 6-trimethyl-phenyl)- 3,7-dimethyl-nona-2,4,6,8- tetraenoic acid | |
| Identifiers | |
| CAS number | 55079-83-9 |
| ATC code | D05BB02 |
| PubChem | 6437841 |
| DrugBank | APRD00778 |
| Chemical data | |
| Formula | C21H26O3 |
| Mol. weight | 326.429 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Acitretin (trade name Soriatane®) is a second generation retinoid. It is taken orally, and is typically used for psoriasis.
It is a metabolite of etretinate, which was used prior to the introduction of acitretin. Etretinate was discontinued because it had a narrow therapeutic index as well as a long elimination half-life (t1/2=120 days), making dosing difficult. In contrast, Acitretin's half-life is approximately 2 days.
Women must avoid becoming pregnant for at least 3 years after discontinuing acitretin. In comparison, etretinate was not recommended at all for women who planned to become pregnant.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
